M&A activity heading into 2027 remains shaped by the current monetary policy environment, with the Federal Reserve’s funds rate and Treasury yields influencing financing costs for acquirers. Lower rates have supported a modest pickup in deal volume compared with prior tightening cycles, particularly in technology and healthcare sectors where revenue growth and margin expansion continue to drive consolidation. Regulatory scrutiny from antitrust authorities remains a key variable, as seen in recent enforcement actions that have extended timelines for large transactions. Trader sentiment reflects this balance, pricing in elevated odds for mid-sized deals closing before year-end while assigning lower implied probabilities to megadeals facing prolonged reviews. Key upcoming catalysts include third-quarter earnings releases that may highlight cash positions available for acquisitions and any FOMC communications clarifying the pace of further policy adjustments.